ArticleScientific reports2019
Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 61 citations in OpenAlex.
- 18:2 Cholesterol Ester is a Novel Prognostic Biomarker of Disease Progression in Multiple Sclerosis.Molecular neurobiology · 2026Article
- MALDI-TOF mass spectrometry imaging of sulfatide lipid expression in the CNS of mice with experimental autoimmune encephalomyelitis.Scientific reports · 2026Article
- Decoding Cerebrospinal Fluid: Integrative Metabolomics Across Multiple Platforms.Methods and protocols · 2026Article
- Cerebrospinal fluid lipid profiles as exploratory biomarkers for pediatric meningitis: a proof-of-concept case series.Frontiers in cellular neuroscience · 2026Article
- Unraveling multiple sclerosis: a hidden interaction between intestinal microbiota and host lipid metabolism.Gut microbes · 2025Review
- Altered lipidomic and metabolomic status in cerebrospinal fluid of children with myelin oligodendrocyte glycoprotein antibody-associated disorder.Biochemistry and biophysics reports · 2025Article
- Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Phospholipids and Sphingolipids in Osteoarthritis.Biomolecules · 2025Review
- Demyelination and Remyelination: General Principles.Advances in neurobiology · 2025Review
- Cerebrospinal fluid metabolomic signatures in paediatric MOGAD and POMS.Frontiers in immunology · 2025Article
- CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Myelin Lipid Alterations in Neurodegenerative Diseases: Landscape and Pathogenic Implications.Antioxidants & redox signaling · 2024Review
- Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis.Metabolites · 2024Review
- Nutritional roles and therapeutic potentials of dietary sphingomyelin in brain diseases.Journal of clinical biochemistry and nutrition · 2024Article
- Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS).International journal of molecular sciences · 2024Article
- Metabolomics of Cerebrospinal Fluid Amino and Fatty Acids in Early Stages of Multiple Sclerosis.International journal of molecular sciences · 2023Article
- Dysregulation of humoral immunity, iron homeostasis, and lipid metabolism is associated with multiple sclerosis progression.Multiple sclerosis and related disorders · 2023Article
- Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- ATR-FTIR spectroscopy of plasma supported by multivariate analysis discriminates multiple sclerosis disease.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a complex multifactorial neuropathology. Although its etiology remains unclear, it has been demonstrated that the immune system attacks myelin, leading to demyelination and axonal damage. The involvement of lipids as one of the main components of myelin sheaths in MS and other demyelinating diseases has been postulated. However, it is still a matter of debate whether specific alteration patterns exist over the disease course. Here, using a lipidomic approach, we demonstrated that, at the time of diagnosis, the cerebrospinal fluid of MS patients presented differences in 155 lipid species, 47 of which were identified. An initial hierarchical clusterization was used to classify MS patients based on the presence of 25 lipids. When a supervised method was applied in order to refine this classification, a lipidomic signature was obtained. This signature was composed of 15 molecules belonging to five different lipid families including fatty acids (FAs). An FA-targeted approach revealed differences in two members of this family: 18:3n3 and 20:0 (arachidic acid). These results reveal a CSF lipidomic signature in MS patients at the time of diagnosis that might be considered as a potential diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.